Gut Dysbiosis Associated With Hepatitis C Virus Infection

Takako Inoue(Kaneka (United States)), Yasuhito Tanaka(Kumamoto University), Rie Momoda(Kyushu University), Shunsuke Nojiri(Nagoya City University), Hitoshi Yoshiji(Nara Medical University), Kei Fujiwara(Nagoya City University), Hideto Kawaratani(Nara Medical University), Kiyoaki Ito(Aichi Medical University), Etsuko Iio(Nagoya City University), Masashi Yoneda(Aichi Medical University), Kei Moriya(Nara Medical University), Jiro Nakayama(Kyushu University)
Clinical Infectious Diseases
March 6, 2018
10.1093/cid/ciy205
Cited by 187

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
|Journal of Gastroenterology|2021|424
Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry Into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP)
|Hepatology|2013|259
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
|Journal of Gastroenterology|2018|242
Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization
|Proceedings of the National Academy of Sciences|2019|241